09:01 AM EDT, 08/22/2024 (MT Newswires) -- Alkermes ( ALKS ) said Thursday it initiated a phase 2 Vibrance-2 study to evaluate the safety and efficacy of ALKS 2680, a once-daily potential treatment for narcolepsy, in comparison to placebo in adult patients with narcolepsy type 2.

Narcolepsy is a neurological disorder due to excessive daytime sleepiness.

The company said it plans to enroll roughly 80 participants with narcolepsy type 2 in the trial throughout the US, Australia, and Europe.

Alkermes ( ALKS ) is initiating the phase 2 trial based on the results from its phase 1 study, Chief Medical Officer Craig Hopkinson said.